Current Front-Line Targeted Treatments in Ph+ ALL

Elias Jabbour, MD, provides an overview of the history of targeted agents and the use of tyrosine kinase inhibitors (TKIs) in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

EP: 1.Overview of Characteristics Unique to Ph+ ALL

EP: 2.Timely Detection: Incidence and Prevalence of Ph+ ALL

EP: 3.Supporting Ph+ ALL Patient: Emotional Challenges and Quality of Life

EP: 4.Screening and Diagnosing of Ph+ ALL in Adults

EP: 5.Diagnosis and Treatment Timeline: Different Phases of Ph+ ALL Management

Now Viewing

EP: 6.Current Front-Line Targeted Treatments in Ph+ ALL

EP: 7.Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients

EP: 8.PhALLCON Trial: Efficacy and Safety of Ponatinib in Ph+ ALL Patients

EP: 9.Value-Based Care Models Optimizing Ph+ ALL Patient Care

EP: 10.Unmet Needs in Screening, Diagnosis, and Management of Ph+ ALL

EP: 11.Disparities in Access to Care for Ph+ ALL patients

EP: 12.The Future of Ph+ ALL Treatments

EP: 13.Concluding Thoughts on Ph+ ALL Treatment

Related Videos

Related Content

Advertisement

June 12th 2025

Zilucoplan Shows Rapid, Durable, Steroid-Sparing Benefits in gMG

Maggie L. Shaw

Zilucoplan (Zilbrysq; UCB) is a once-daily subcutaneous C5 complement inhibitor that has demonstrated long-term treatment benefits in patients who have acetylcholine receptor antibody–positive generalized myasthenia gravis (gMG).

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

June 10th 2025

Fixed-Duration SC Mosunetuzumab Shows 83% PFS at 1 Year in Untreated HTB Follicular Lymphoma

Mary Caffrey

Data presented at ASCO are the latest positive results for a subcutaneous version of this bispecific T-cell engager, which faces competition in follicular lymphoma.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 6th 2025

Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?

Mary Caffrey

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.

June 6th 2025

Oral Ivarmacitinib Shows Promise in Atopic Dermatitis

Maggie L. Shaw

Ivarmacitinib, also known as oral SHR0302, is not yet approved by the FDA, with trials currently exploring its utility in disease settings that include atopic dermatitis and rheumatoid arthritis.

Related Content

Advertisement

June 12th 2025

Zilucoplan Shows Rapid, Durable, Steroid-Sparing Benefits in gMG

Maggie L. Shaw

Zilucoplan (Zilbrysq; UCB) is a once-daily subcutaneous C5 complement inhibitor that has demonstrated long-term treatment benefits in patients who have acetylcholine receptor antibody–positive generalized myasthenia gravis (gMG).

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

June 10th 2025

Fixed-Duration SC Mosunetuzumab Shows 83% PFS at 1 Year in Untreated HTB Follicular Lymphoma

Mary Caffrey

Data presented at ASCO are the latest positive results for a subcutaneous version of this bispecific T-cell engager, which faces competition in follicular lymphoma.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 6th 2025

Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?

Mary Caffrey

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.

June 6th 2025

Oral Ivarmacitinib Shows Promise in Atopic Dermatitis

Maggie L. Shaw

Ivarmacitinib, also known as oral SHR0302, is not yet approved by the FDA, with trials currently exploring its utility in disease settings that include atopic dermatitis and rheumatoid arthritis.